Matthew E Burow Selected Research

3- (4- chlorophenyl)- adamantane- 1- carboxylic acid (pyridin-4-ylmethyl)amide

2/2014	Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival.
7/2012	Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer.
4/2011	Targeting NFĸB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2.
11/2010	Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew E Burow Research Topics

Disease

78	Breast Neoplasms (Breast Cancer) 10/2022 - 08/2002
78	Neoplasms (Cancer) 10/2022 - 05/2004
20	Neoplasm Metastasis (Metastasis) 03/2022 - 01/2008
20	Carcinogenesis 01/2019 - 06/2008
17	Triple Negative Breast Neoplasms 01/2022 - 05/2012
7	Obesity 03/2019 - 01/2013
5	Carcinoma (Carcinomatosis) 01/2019 - 07/2011
3	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 05/2011
3	Osteoporosis 04/2017 - 08/2014
3	Hepatocellular Carcinoma (Hepatoma) 10/2011 - 12/2002
3	Ovarian Neoplasms (Ovarian Cancer) 01/2010 - 12/2006
3	Adenocarcinoma 05/2006 - 07/2002
2	Disease Progression 01/2021 - 09/2016
2	Uterine Neoplasms (Uterine Cancer) 01/2019 - 02/2014
2	Inflammation (Inflammations) 02/2015 - 04/2009
2	Glioblastoma (Glioblastoma Multiforme) 10/2011 - 07/2011
2	Hypoxia (Hypoxemia) 01/2009 - 12/2002
1	Desmoplastic Small Round Cell Tumor 04/2022
1	Genetic Translocation (Chromosomal Translocation) 04/2022

Drug/Important Bio-Agent (IBA)

29	Estrogens (Estrogen)FDA Link 10/2022 - 12/2002
25	Estrogen ReceptorsIBA 03/2022 - 09/2006
16	Hormones (Hormone)IBA 03/2022 - 06/2008
16	Pharmaceutical PreparationsIBA 01/2022 - 09/2009
13	MicroRNAs (MicroRNA)IBA 01/2021 - 11/2011
12	Estrogen Receptor alphaIBA 10/2022 - 05/2005
11	Phosphotransferases (Kinase)IBA 04/2022 - 07/2011
11	Proteins (Proteins, Gene)FDA Link 01/2022 - 08/2002
11	Tamoxifen FDA LinkGeneric 06/2021 - 09/2006
9	p38 Mitogen-Activated Protein KinasesIBA 01/2019 - 12/2002
7	Progesterone Receptors (Progesterone Receptor)IBA 01/2021 - 12/2006
7	Mitogen-Activated Protein KinasesIBA 01/2021 - 10/2012
6	glyceollinIBA 03/2022 - 01/2006
6	Biological ProductsIBA 01/2022 - 09/2009
5	Phenobarbital (Luminal)FDA Link 08/2021 - 07/2012
5	LeptinIBA 03/2019 - 01/2013
5	SphingolipidsIBA 02/2014 - 11/2009
5	PhytoalexinsIBA 02/2013 - 01/2006
5	sphingosine kinaseIBA 07/2012 - 11/2010
4	Messenger RNA (mRNA)IBA 01/2022 - 12/2002
4	LigandsIBA 05/2021 - 01/2010
4	Fulvestrant (Faslodex)FDA Link 05/2021 - 01/2010
4	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 03/2005
4	PanobinostatIBA 01/2020 - 05/2012
4	Protein Isoforms (Isoforms)IBA 09/2016 - 12/2010
4	DDTIBA 01/2015 - 01/2009
4	3- (4- chlorophenyl)- adamantane- 1- carboxylic acid (pyridin-4-ylmethyl)amideIBA 02/2014 - 11/2010
4	CeramidesIBA 06/2012 - 05/2004
3	RNA (Ribonucleic Acid)IBA 10/2022 - 01/2013
3	Aromatase InhibitorsIBA 03/2022 - 01/2013
3	Letrozole (Femara)FDA LinkGeneric 03/2022 - 01/2013
3	CollagenIBA 01/2022 - 01/2021
3	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2006
3	matrigelIBA 01/2021 - 01/2010
3	Histone Deacetylase InhibitorsIBA 01/2020 - 01/2012
3	Small Interfering RNA (siRNA)IBA 01/2019 - 06/2008
3	MelatoninIBA 01/2019 - 05/2005
3	ClaudinsIBA 06/2018 - 08/2016
3	SphingosineIBA 02/2014 - 05/2004
3	ProteomeIBA 03/2012 - 01/2008
2	Transcription Factors (Transcription Factor)IBA 04/2022 - 08/2021
2	MitogensIBA 01/2022 - 01/2012
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2022 - 01/2022
2	AndrogensIBA 01/2022 - 02/2014
2	romidepsin (FK228)FDA Link 01/2022 - 01/2020
2	Androgen Receptors (Androgen Receptor)IBA 01/2022 - 05/2011
2	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 06/2021 - 01/2021
2	PlasticsIBA 01/2021 - 07/2012
2	Metalloproteases (Metalloproteinases)IBA 01/2021 - 01/2019
2	Matrix Metalloproteinases (MMPs)IBA 01/2021 - 08/2015
2	Cadherins (E-Cadherin)IBA 11/2017 - 12/2015
2	Cyclin D1IBA 11/2017 - 11/2009
2	Estradiol (Delestrogen)FDA LinkGeneric 01/2017 - 09/2012
2	Endocrine DisruptorsIBA 01/2016 - 01/2012
2	CytokinesIBA 02/2015 - 06/2004
2	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 02/2015 - 09/2006
2	ChemokinesIBA 02/2015 - 01/2011
2	daidzeinIBA 08/2014 - 08/2010
2	Death Domain ReceptorsIBA 04/2013 - 01/2012
2	Progesterone FDA LinkGeneric 02/2013 - 05/2012
2	PhytochemicalsIBA 02/2013 - 09/2009
2	flavoneIBA 10/2012 - 07/2002
2	Chalcone (Benzalacetophenone)IBA 10/2012 - 07/2002
2	Collagen Type I (Type I Collagen)IBA 07/2012 - 07/2011
2	Insulin (Novolin)FDA Link 06/2012 - 01/2012
2	EnzymesIBA 06/2012 - 06/2011
2	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 06/2012 - 06/2011
2	afimoxifene (hydroxytamoxifen)IBA 03/2012 - 01/2010
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2012 - 12/2002
2	Sorafenib (BAY 43-9006)FDA Link 10/2011 - 07/2011
2	Pemetrexed (MTA)FDA Link 10/2011 - 07/2011
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 09/2006 - 12/2002
2	Estrogen Receptor betaIBA 09/2006 - 05/2006
2	ApigeninIBA 03/2005 - 07/2002
2	NF-kappa B (NF-kB)IBA 06/2004 - 12/2002
2	LuciferasesIBA 12/2002 - 12/2002
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 12/2002 - 07/2002
1	SaltsIBA 04/2022

Therapy/Procedure

35	Therapeutics 10/2022 - 08/2004
4	Drug Therapy (Chemotherapy) 01/2012 - 01/2008
3	Lasers (Laser) 11/2017 - 09/2015